1416 related articles for article (PubMed ID: 9435201)
61. Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
Prather PL; Tsai AW; Law PY
J Pharmacol Exp Ther; 1994 Jul; 270(1):177-84. PubMed ID: 8035314
[TBL] [Abstract][Full Text] [Related]
62. Inhibitory actions of delta 1-, delta 2-, and mu-opioid receptor agonists on excitatory transmission in lamina II neurons of adult rat spinal cord.
Glaum SR; Miller RJ; Hammond DL
J Neurosci; 1994 Aug; 14(8):4965-71. PubMed ID: 8046463
[TBL] [Abstract][Full Text] [Related]
63. Continuous intrathecal opioid analgesia: tolerance and cross-tolerance of mu and delta spinal opioid receptors.
Russell RD; Leslie JB; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1987 Jan; 240(1):150-8. PubMed ID: 3027302
[TBL] [Abstract][Full Text] [Related]
64. Intrathecal pre-administration of fentanyl effectively suppresses formalin evoked c-Fos expression in spinal cord of rat.
Nakamura T; Takasaki M
Can J Anaesth; 2001 Nov; 48(10):993-9. PubMed ID: 11698319
[TBL] [Abstract][Full Text] [Related]
65. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
66. 7-Benzylidenenaltrexone (BNTX): a selective delta 1 opioid receptor antagonist in the mouse spinal cord.
Sofuoglu M; Portoghese PS; Takemori AE
Life Sci; 1993; 52(8):769-75. PubMed ID: 8383271
[TBL] [Abstract][Full Text] [Related]
67. Opioid effects on spinal [3H]5-hydroxytryptamine release are not related to their antinociceptive action.
Monroe PJ; Kradel BK; Smith DL; Smith DJ
Eur J Pharmacol; 1995 Jan; 272(1):51-6. PubMed ID: 7713149
[TBL] [Abstract][Full Text] [Related]
68. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
69. Noradrenergic modulation of noxious heat-evoked fos-like immunoreactivity in the dorsal horn of the rat sacral spinal cord.
Jones SL
J Comp Neurol; 1992 Nov; 325(3):435-45. PubMed ID: 1360018
[TBL] [Abstract][Full Text] [Related]
70. Induction of Fos-like immunoreactivity by opioids in guinea-pig brain.
Bot G; Chahl LA
Brain Res; 1996 Aug; 731(1-2):45-56. PubMed ID: 8883853
[TBL] [Abstract][Full Text] [Related]
71. Selective antagonism by naltrindole of the antinociceptive effects of the delta opioid agonist cyclic[D-penicillamine2-D-penicillamine5]enkephalin in the rat.
Drower EJ; Stapelfeld A; Rafferty MF; de Costa BR; Rice KC; Hammond DL
J Pharmacol Exp Ther; 1991 Nov; 259(2):725-31. PubMed ID: 1658309
[TBL] [Abstract][Full Text] [Related]
72. Morphine-induced in vivo release of spinal cholecystokinin is mediated by delta-opioid receptors--effect of peripheral axotomy.
Gustafsson H; Afrah AW; Stiller CO
J Neurochem; 2001 Jul; 78(1):55-63. PubMed ID: 11432973
[TBL] [Abstract][Full Text] [Related]
73. Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration.
Craft RM; Henley SR; Haaseth RC; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1995 Dec; 275(3):1535-42. PubMed ID: 8531126
[TBL] [Abstract][Full Text] [Related]
74. [Interaction between opiate subtypes and serotonin in suppressing noxiously evoked activity of WDR neurons].
Nakatani K; Kitahata LM; Harada Y; Omote K; Collins JG; Yuge O
Masui; 1995 Jun; 44(6):795-9. PubMed ID: 7637153
[TBL] [Abstract][Full Text] [Related]
75. Mu opioid antagonist properties of a cyclic somatostatin octapeptide in vivo: identification of mu receptor-related functions.
Shook JE; Pelton JT; Lemcke PK; Porreca F; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Jul; 242(1):1-7. PubMed ID: 2886635
[TBL] [Abstract][Full Text] [Related]
76. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective mu or delta opioid agonists in mice.
Bilsky EJ; Inturrisi CE; Sadée W; Hruby VJ; Porreca F
Pain; 1996 Dec; 68(2-3):229-37. PubMed ID: 9121809
[TBL] [Abstract][Full Text] [Related]
77. Agonist and antagonist profiles of [D-Ala2,Glu4]deltorphin and its [Cys4]- and [Ser4]-substituted derivatives: further evidence of opioid delta receptor multiplicity.
Horan PJ; Wild KD; Misicka A; Lipkowski A; Haaseth RC; Hruby VJ; Weber SJ; Davis TP; Yamamura HI; Porreca F
J Pharmacol Exp Ther; 1993 May; 265(2):896-902. PubMed ID: 8388462
[TBL] [Abstract][Full Text] [Related]
78. Spinal pharmacology of antinociception produced by microinjection of mu or delta opioid receptor agonists in the ventromedial medulla of the rat.
Hurley RW; Banfor P; Hammond DL
Neuroscience; 2003; 118(3):789-96. PubMed ID: 12710986
[TBL] [Abstract][Full Text] [Related]
79. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
Shook JE; Pelton JT; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
[TBL] [Abstract][Full Text] [Related]
80. Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors.
Shook JE; Kazmierski W; Wire WS; Lemcke PK; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1988 Sep; 246(3):1018-25. PubMed ID: 2843623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
